Both preclinical studies and early results from clinical trials have demonstrated how targeting CD47, especially in combination with other approved AML therapies to promote phagocytosis, offers promising hope as an LSC-targeting therapy that could lead to durable remissions. This evidence concerns the gene CD47 and acute myeloid leukemia.